Session » Systemic Lupus Erythematosus – Animal Models Poster

Date: Tuesday, November 7, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2561

BTK Inhibition Ameliorates Renal Disease in Spontaneous Murine Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2576

Caspase 8 in Dendritic Cells Suppresses IRF5 Activation through Endosomal TLR Signaling to Prevent SLE-like Disease

9:00AM-11:00AM: Abstract Number: 2558

DNA Methylation-Dependent Regulation of Cathepsin E Gene Expression By the Transcription Factor Kaiso in MRL/Lpr Mice

9:00AM-11:00AM: Abstract Number: 2580

Exploiting Inhibition of PD1 Signaling in a Murine Model of Anti-SSA/Ro Associated Congenital Heart Block

9:00AM-11:00AM: Abstract Number: 2571

IL23 Deficiency Alters Thymic Selection in Lupus Prone Mice

9:00AM-11:00AM: Abstract Number: 2564

Inhibition of Neutrophil Elastase Protects Against Glomerulonephritis and Thrombosis in a Mouse Model of Lupus

9:00AM-11:00AM: Abstract Number: 2562

Inhibition of Spleen Tyrosine Kinase Improves Renal Pathology and Reduces Lymphocyte Activation in the MRL/Lpr and NZB/NZW Murine Models of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2574

Interleukin-33 Ameliorates Murine Lupus Via Induction of Regulatory T Cells and M2 Macrophage Polarisation

9:00AM-11:00AM: Abstract Number: 2559

KZR-616, a Selective Inhibitor of the Immunoproteasome, Blocks the Disease Progression in Multiple Models of Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 2573

Lack of CD137-CD137 Ligand Signalling Aggravates Glomerulonephritis and Reduces the Survival of Lupus-Prone B6.MRLlpr Mice

9:00AM-11:00AM: Abstract Number: 2566

Myxomavirus-Derived Serpin (Serp-1) Reduces Diffuse Alveolar Hemorrhage in a Murine Model of Lupus

9:00AM-11:00AM: Abstract Number: 2565

Pharmacodynamic Modeling of BTK Occupancy Versus Efficacy in Ra and SLE Models Using the Novel Specific BTK Inhibitor Evobrutinib

9:00AM-11:00AM: Abstract Number: 2568

Prophylactic and Therapeutic Administration of a JAK1-Selective Inhibitor Blocks and Reverses Nephritis and Sialadenitis in NZB/W-F1 Mice

9:00AM-11:00AM: Abstract Number: 2572

Rab4a Control over Glycolytic Metabolism and T-Cell Lineage Specification Protects from Intra-Alveolar Hemorrhage in Mouse Model of SLE

9:00AM-11:00AM: Abstract Number: 2578

RAB4A Protects from Antinuclear Antibody Production and Nephritis in the Pristane-Induced Model of SLE

9:00AM-11:00AM: Abstract Number: 2579

Rock-Mediated Pkca Nuclear Translocation Is Important in Neutrophil Netosis and UVB Induced-Skin Inflammation

9:00AM-11:00AM: Abstract Number: 2577

Segmented Filamentous Bacteria Colonization Exacerbate Lupus Nephritis in NZM2410 Mice and Causes an Expansion of Intestinal Group 3 Innate Lymphoid Cells

9:00AM-11:00AM: Abstract Number: 2569

Serine/Arginine-Rich Splicing Factor 1 (SRSF1) Is a Novel Regulator of T Cell Function and Its Selective Deficiency in T Lymphocytes Leads to Autoimmunity and Lupus-like Nephritis

9:00AM-11:00AM: Abstract Number: 2563

SH3BP2 Gain-of-Function Mutation Ameliorates Lupus in B6.MRL-Faslpr Mice

9:00AM-11:00AM: Abstract Number: 2560

Spleen Tyrosine Kinase Inhibition Reveals Immune Cell Subsets of Diseased NZB/W F1 Mice That Are Reflected in Systemic Lupus Erythematosus Patient Peripheral Blood Mononuclear Cells

9:00AM-11:00AM: Abstract Number: 2570

The Functional Consequence of Human (hu)TLR8 on Macrophage Immunometabolism and Renal Inflammation in Murine Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2575

The Role of Interferon in Autoimmune-Susceptible Ro60 Knockout Mice

9:00AM-11:00AM: Abstract Number: 2567

Type I IFN Blockade Restores Normal Transitional B Cell Development Post-Anti-CD20 Depletion

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].